Protein kinase CA determines HER2 fate in breast carcinoma cells with HER2 protein overexpression without gene amplification

Cancer Research

Volumn 67, Issue 11, 2007, Pages 5308-5317

  Magnifico, Alessandra ^a   Albano, Luisa ^a   Campaner, Stefano ^b   Campiglio, Manuela ^a   Pilotti, Silvana ^a   Ménard, Sylvie ^a   Tagliabue, Elda ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; PROTEIN KINASE C ALPHA; PROTEIN TYROSINE KINASE INHIBITOR; SMALL INTERFERING RNA; UBIQUITIN; 12 (2 CYANOETHYL) 6,7,12,13 TETRAHYDRO 13 METHYL 5 OXOINDOLO[2,3 A]PYRROLO[3,4 C]CARBAZOLE; CARBAZOLE DERIVATIVE; CBL PROTEIN; CBL PROTEIN, HUMAN; ENZYME INHIBITOR; EPIDERMAL GROWTH FACTOR; INDOLE DERIVATIVE; MESSENGER RNA; UNCLASSIFIED DRUG;

ARTICLE; BREAST CARCINOMA; CANCER CELL; CELL SURFACE; CHEMICAL ANALYSIS; CONTROLLED STUDY; DEREGULATION; DOWN REGULATION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GENE AMPLIFICATION; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN TISSUE; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION; BIOSYNTHESIS; BREAST TUMOR; DRUG ANTAGONISM; ENZYMOLOGY; GENETIC TRANSFECTION; GENETICS; IMMUNOPRECIPITATION; METABOLISM; TUMOR CELL LINE;

BREAST NEOPLASMS; CARBAZOLES; CELL LINE, TUMOR; ENZYME INHIBITORS; EPIDERMAL GROWTH FACTOR; GENE AMPLIFICATION; HUMANS; IMMUNOPRECIPITATION; INDOLES; PROTEIN KINASE C-ALPHA; PROTO-ONCOGENE PROTEINS C-CBL; RECEPTOR, ERBB-2; RNA, MESSENGER; RNA, SMALL INTERFERING; TRANSFECTION;

EID: 34347226346     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-3936     Document Type: Article

References (47)

1. Marmor MD, Skaria KB, Yarden Y. Signal transduction and oncogenesis by ErbB/HER receptors. Int J Radiat Oncol Biol Phys 2004;58:903-13.
2. Harari D, Yarden Y. Molecular mechanisms underlying ErbB2/HER2 action in breast cancer. Oncogene 2000;19:6102-14.
3. Tagliabue E, Agresti R, Carcangiu ML, et al. Role of HER2 in wound-induced breast carcinoma proliferation. Lancet 2003;362:527-33.
4. Mezzelani A, Alasio L, Bartoli C, et al. c-erbB2/neu gene and chromosome 17 analysis in breast cancer by FISH on archival cytological fine-needle aspirates. Br J Cancer 1999;80:519-25.
5. Ménard S, Balsari A, Casalini P, et al. HER2-positive breast carcinomas as a particular subset with peculiar clinical behaviors. Clin Cancer Res 2002;8:520-5.
6. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraitsof human breast tumours. Nature 2000;406:747-52.
7. Van'T Veer LJ, Dai H, Van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415:530-6.
8. Citri A, Skaria KB, Yarden Y. The deaf and the dumb: the biology of ErbB-2 and ErbB-3. Exp Cell Res 2003;284:54-65.
9. Konecny GE, Pegram MD, Venkatesan N, et al. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res 2006;66:1630-9.
10. Koivunen J, Aaltonen V, Peltonen J. Protein kinase C (PKC) family in cancer progression. Cancer Lett 2006;235:1-10.
11. Ways DK, Kukoly CA, deVente J, et al. MCF-7 breast cancer cells transfected with protein kinase C-α exhibit altered expression of other protein kinase C isoforms and display a more aggressive neoplastic phenotype. J Clin Invest 1995;95:1906-15.
12. Mandil R, Ashkenazi E, Blass M, et al. Protein kinase Cα and protein kinase Cδ play opposite roles in the proliferation and apoptosis of glioma cells. Cancer Res 2001;61:4612-9.
13. Vallentin A, Prevostel C, Fauquier T, Bonnefont X, Joubert D. Membrane targeting and cytoplasmic sequestration in the spatiotemporal localization of human protein kinase Cα. J Biol Chem 2000;275:6014-21.
14. Michie AM, Nakagawa R. The link between PKCα regulation and cellular transformation. Immunol Lett 2005;96:155-62.
15. Bao J, Alroy I, Waterman H, et al. Threonine phosphorylation diverts internalized epidermal growth factor receptorsfrom a degradative pathway to the recycling endosome. J Biol Chem 2000;275:26178-86.
16. Rhodes A, Jasani B, Couturier J, et al. A formalin-fixed, paraffin-processed cell line standard for quality control of immunohistochemical assay of HER-2/neu expression in breast cancer. Am J Clin Pathol 2002;117:81-9.
17. Tagliabue E, Centis F, Campiglio M, et al. Selection of monoclonal antibodies which induce internalization and phosphorylation of p185HER2 and growth inhibition of cells with HER2/neu gene amplification. Int J Cancer 1991;47:933-7.
18. Henegariu O, Heerema NA, Lowe WL, Bray-Ward P, Ward DC, Vance GH. Improvementsi n cytogenetic slide preparation: controlled chromosome spreading, chemical aging and gradual denaturing. Cytometry 2001;43:101-9.
19. Dagrada GP, Mezzelani A, Alasio L, et al. HER-2/neu assessment in primary chemotherapy treated breast carcinoma: no evidence of gene profile changing. Breast Cancer Res Treat 2003;80:207-14.
20. Castiglioni F, Terenziani M, Carcangiu ML, et al. Radiation effectson development of HER2-positive breast carcinomas. Clin Cancer Res 2007;13:46-51.
21. Castiglioni F, Tagliabue E, Campiglio M, Pupa SM, Balsari A, Ménard S. Role of exon-16-deleted HER2 in breast carcinomas. Endocr Relat Cancer 2006;13:221-32.
22. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001;29:e45.
23. Luttrell LM, Hawes BE, Van Biesen T, Luttrell DK, Lansing TJ, Lefkowitz RJ. Role of c-Src tyrosine kinase in G protein-coupled receptor- and Ghγ subunit-mediated activation of mitogen-activated protein kinases. J Biol Chem 1996;271:19443-50.
24. Belsches-Jablonski AP, Biscardi JS, Peavy DR, Tice DA, Romney DA, Parsons SJ. Src family kinases and HER2 interactionsin human breast cancer cell growth and survival. Oncogene 2001;20:1465-75.
25. Levkowitz G, Waterman H, Ettenberg SA, et al. Ubiquitin ligase activity and tyrosine phosphorylation underlie suppression of growth factor signaling by c-Cbl/Sli-1. Mol Cell 1999;4:1029-40.
26. Levkowitz G, Oved S, Klapper LN, et al. c-Cbl isa suppressor of the neu oncogene. J Biol Chem 2000;275:35532-9.
27. Keshamouni VG, Mattingly RR, Reddy KB. Mechanism of 17-β-estradiol- induced Erk1/2 activation in breast cancer cells. A role for HER2 AND PKC-δ. J Biol Chem 2002;277:22558-65.
28. Guillemain I, Rossignol B. Protein kinase C and phospholipase D activation in rat parotid glands. FEBS Lett 1995;363:13-6.
29. Gauthier ML, Torretto C, Ly J, Francescutti V, O'Day DH. Protein kinase Cα negatively regulates cell spreading and motility in MDA-MB-231 human breast cancer cells downstream of epidermal growth factor receptor. Biochem Biophys Res Commun 2003;307:839-46.
30. Xu W, Marcu M, Yuan X, Mimnaugh E, Patterson C, Neckers L. Chaperone-dependent E3 ubiquitin ligase CHIP mediates a degradative pathway for c-ErbB2/Neu. Proc Natl Acad Sci U S A 2002;99:12847-52.
31. Levkowitz G, Klapper LN, Tzahar E, Freywald A, Sela M, Yarden Y. Coupling of the c-Cbl protooncogene product to ErbB-1/EGF-receptor but not to other ErbB proteins. Oncogene 1996;12:1117-25.
32. Marmor MD, Yarden Y. Role of protein ubiquitylation in regulating endocytosis of receptor tyrosine kinases. Oncogene 2004;23:2057-70.
33. Hommelgaard AM, Lerdrup M, van Deurs B. Association with membrane protrusions makes ErbB2 an internalization-resistant receptor. Mol Biol Cell 2004;15:1557-67.
34. Round JL, Tomassian T, Zhang M, Patel V, Schoenberger SP, Miceli MC. Dlgh1 coordinates actin polymerization, synaptic T cell receptor and lipid raft aggregation, and effector function in T cells. J Exp Med 2005;201:419-30.
35. Prevostel C, Alice V, Joubert D, Parker PJ. Protein kinase C(α) actively downregulates through caveolae-dependent traffic to an endosomal compartment. J Cell Sci 2000;113:2575-84.
36. Couet J, Sargiacomo M, Lisanti MP. Interaction of a receptor tyrosine kinase, EGF-R, with caveolins - caveolin binding negatively regulatesty rosine and serine/threonine kinase activities. J Biol Chem 1997;272:30429-38.
37. Simons K, Toomre D. Lipid rafts and signal transduction. Nat Rev Mol Cell Biol 2000;1:31-9.
38. Lafont F, Simons K. Raft-partitioning of the ubiquitin ligases Cbl and Nedd4 upon IgE-triggered cell signaling. Proc Natl Acad Sci U S A 2001;98:3180-4.
39. Sigismund S, Woelk T, Puri C, et al. Clathrin-independent endocytosis of ubiquitinated cargos. Proc Natl Acad Sci U S A 2005;102:2760-5.
40. Aguilar RC, Wendland B. Endocytosis of membrane receptors: two pathways are better than one. Proc Natl Acad Sci U S A 2005;102:2679-80.
41. Polo S, Pece S, Di Fiore PP. Endocytosis and cancer. Curr Opin Cell Biol 2004;16:156-61.
42. Austin CD, De Maziere AM, Pisacane PI, et al. Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin. Mol Biol Cell 2004;15:5268-82.
43. Nanjundan M, Sun J, Zhao J, Zhou Q, Sims PJ , Wiedmer T. Plasma membrane phospholipid scramblase 1 promotes EGF-dependent activation of c-Src through the epidermal growth factor receptor. J Biol Chem 2003;278:37413-8.
44. Tan M, Li P, Sun M, Yin G, Yu D. Upregulation and activation of PKCα by ErbB2 through Src promotes breast cancer cell invasion that can be blocked by combined treatment with PKCα and Src inhibitors. Oncogene 2006;25:3286-95.
45. Magnifico A, Ettenberg S, Yang C, et al. WW domain HECT E3s target Cbl RING finger E3s for proteasomal degradation. J Biol Chem 2003;278:43169-77.
46. Ettenberg SA, Magnifico A, Cuello M, et al. Cbl-b-dependent coordinated degradation of the epidermal growth factor receptor signaling complex. J Biol Chem 2001;276:27677-84.
47. Ryan PE, Davies GC, Nau MM, Lipkowitz S. Regulating the regulator: negative regulation of Cbl ubiquitin ligases. Trends Biochem Sci 2006;31:79-88.